Overview
- FDA staff reviewers published findings on June 30 saying the scientific evidence is weak and does not support allowing compounding pharmacies to manufacture seven widely marketed peptides.
- The seven substances under review include BPC-157, TB-500, KPV, MOTS-c, emideltide, semax and epitalon, and reviewers flagged gaps such as few or no human trials, unclear impurity testing, and risks of immune reactions from injected formulations.
- The agency named a new Pharmacy Compounding Advisory Committee roster that largely includes clinicians, pharmacists and clinic owners with financial ties to peptide clinics and sellers, raising questions about potential conflicts of interest.
- Peptides are sold online and at wellness clinics for muscle, healing and anti-aging claims despite limited evidence, and sellers often label products 'for research use only' to avoid FDA regulation, which could leave consumers exposed to untested doses or contaminants.
- The panel’s July 23–24 recommendation is non-binding but typically informs FDA policy, and observers will watch whether the committee departs from earlier panels that voted against permitting peptides after a 2023 federal restriction citing safety and quality concerns.